Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03699644 · ClinicalTrials.gov registry record

Multimodal Ocular Imaging in Neurodegeneration

A clinical trial, sponsored by University of Michigan.

Completed
Registry status
16
Enrollment target

NCT03699644: Completed study, sponsored by University of Michigan.

NCT03699644 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03699644 has completed, sponsored by University of Michigan.

COMPLETED
Registry status
16 participants
Enrollment target

Study Summary

Alzheimer's disease (AD) and frontotemporal dementia (FTD) are two of the most common types of age-related neurodegenerative disorders. Identifying at-risk patients and gauging disease progression in a non-invasive manner would be invaluable. Early and correct diagnosis is crucial for coordinating supportive care, patient expectations, caregiver arrangements and family planning. In addition, as treatments become available, beginning therapy early in the disease before symptoms become severe will be important. Multimodal ocular imaging (MOI) includes an ophthalmic (eye) exam and eye photographs to evaluate different layers of the retina, which is the light sensing layer of the eye. Newer technologies make it possible to visualize the disease process occurring in AD and FTD by using MOI to look at the retina, since the retina is fundamentally an outward extension of the brain itself. This study will attempt to correlate signs of disease in the retina, as determined by MOI, with plaque buildup in the brain as seen by imaging. This will demonstrate the sensitivity and specificity of MOI for diagnosing AD and FTD in a noninvasive manner.

Primary Outcome

Imaging of the eye will be used to measure differences in retinal thickness between subjects with Alzheimer's Dementia, Frontotemporal Dementia, and healthy age-matched controls.

Interventions

  • DEVICE Magnetic Resonance Imaging (MRI)
  • DEVICE Spectral-Domain Optical Coherence Tomography (SD-OCT)
  • DEVICE Positron Emission Tomography (PET)
  • DIAGNOSTIC_TEST Comprehensive Ophthalmic Examination
  • DEVICE Fundus Photography

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2019-01-04
Est. Completion 2019-04-03
University of Michigan

1,327 total trials

What the finished NCT03699644 record still lists

NCT03699644 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.

The record links to 0 conditions, and to 5 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.

NCT03699644 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03699644 about?

NCT03699644 is a clinical study titled "Multimodal Ocular Imaging in Neurodegeneration". Alzheimer's disease (AD) and frontotemporal dementia (FTD) are two of the most common types of age-related neurodegenerative disorders. Identifying at-risk patients and gauging disease progression in a non-invasive manner would be invaluable. Early and correct diagnosis is crucial for coordinating s...

What is the current status of trial NCT03699644?

This trial is currently completed. The enrollment target is 16 participants. The study started on 2019-01-04. Estimated completion is 2019-04-03.

What interventions are being tested in trial NCT03699644?

The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DEVICE), Spectral-Domain Optical Coherence Tomography (SD-OCT) (DEVICE), Positron Emission Tomography (PET) (DEVICE), Comprehensive Ophthalmic Examination (DIAGNOSTIC_TEST), Fundus Photography (DEVICE).

Who is sponsoring clinical trial NCT03699644?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03699644, the US trial registry maintained by the National Library of Medicine. NCT03699644 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.